Literature DB >> 11155806

Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis.

B Boss1, G Neeck.   

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood, especially IL-6, but also IL-1 alpha and TNF alpha, for example, in different concentrations, depending on disease activity. A disturbed circadian rhythm of cortisol secretion and an overall elevated cortisol release in active RA, depending on disease activity, is known. The presented study examined correlations of IL-6 as the most important systemic mediator of the acute phase response in active RA with classical humoral disease activity parameters, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and with serum cortisol. We investigated 64 active RA patients, previously untreated with glucocorticoids. IL-6 was measured by ELISA from Pharmingen (San Diego), ESR by the method of Westergren and CRP by nephelometry (Behring Marburg, Germany). Cortisol was measured in 34 of these patients, using a fluorescence-polarization immunoassay (FPIA) from Abbott. We found correlations of IL-6 with CRP (p < 0.001, Spearman Rank Test, rs = 0.75), with ESR (p < 0.001, rs = 0.62) and with serum cortisol (p = 0.019, rs = 0.401). ESR and CRP correlate (p < 0.001, rs = 0.8) and cortisol also correlates with ESR (p = 0.002, rs = 0.52) and CRP (p < 0.001, rs = 0.57). IL-6 as an important systemic mediator of inflammation in RA correlates closely with CRP, as it induces its production, and with ESR. These three parameters correlate well with serum cortisol, which is increased in active RA, depending on disease activity. Thus, IL-6 is an important disease activity parameter in RA that is closely related to both the classical humoral disease activity and the HPA axis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155806     DOI: 10.1007/s003930070020

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  6 in total

1.  Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.

Authors:  Patricia A Fair; Erin Driscoll; Meagan A M Mollenhauer; Sarah G Bradshaw; Se Hun Yun; Kurunthachalam Kannan; Gregory D Bossart; Deborah E Keil; Margie M Peden-Adams
Journal:  J Immunotoxicol       Date:  2011-01-24       Impact factor: 3.000

2.  Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.

Authors:  Markus Rehberg; Clemens Giegerich; Amy Praestgaard; Hubert van Hoogstraten; Melitza Iglesias-Rodriguez; Jeffrey R Curtis; Jacques-Eric Gottenberg; Andreas Schwarting; Santos Castañeda; Andrea Rubbert-Roth; Ernest H S Choy
Journal:  Rheumatol Ther       Date:  2021-09-14

3.  The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.

Authors:  Chokchai Thanadetsuntorn; Pintip Ngamjanyaporn; Chavachol Setthaudom; Kenneth Hodge; Nisara Saengpiya; Prapaporn Pisitkun
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

4.  Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.

Authors:  Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

5.  Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1.

Authors:  Helena Forsblad D'Elia; Lars-Ake Mattsson; Claes Ohlsson; Elisabeth Nordborg; Hans Carlsten
Journal:  Arthritis Res Ther       Date:  2003-05-01       Impact factor: 5.156

6.  Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.

Authors:  Yuxuan Li; Lin Yuan; Jie Yang; Yue Lei; Hui Zhang; Liping Xia; Hui Shen; Jing Lu
Journal:  Mediators Inflamm       Date:  2019-10-24       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.